[Effect of naftidrofuryl oxalate (LS-121) on experimental amnesia model in rats].
Effects of naftidrofuryl oxalate (LS-121) on experimental amnesia models, which were induced by cycloheximide (CXM), scopolamine (SCOP) and basal-forebrain (BF) lesion, were investigated using the step-through passive avoidance response in rats. In the retention test, a cut-off time of 600 sec was employed for the measurement of step-through latency (STL). The animals, that showed over 300 sec of STL was regarded as having the criterion of memory retention (% of retention). Increase in both parameters of STL and % of retention was regarded to indicate that the drug was able to improve the amnesia. If only one of the two parameters was increased, we considered that the drug had a tendency to improve the amnesia. Pretraining, post-training and pre-retention treatment of LS-121 (25 mg/kg) improved CXM- and SCOP-induced amnesia. Post-training treatment of LS-121 (25 mg/kg) showed a tendency to improve the BF lesion-induced amnesia. These results suggest that the antiamnesic action of LS-121 may be produced through an activation of the acetylcholinergic neuronal system. Since it improved the amnesia when administered in the pre-retention test, there is a possibility that LS-121 has not only a protective effect, but also a therapeutic effect. Furthermore, it is suggested that LS-121 may also have a therapeutic effect on Alzheimer's disease, since it showed a tendency to improve the BF lesion-induced amnesia.
Kameyama
T
T
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Meijo University, Nagoya, Japan.
Nabeshima
T
T
Katoh
A
A
Ogawa
S
S
D000647:Amnesia / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology; D000818:Animals; D001362:Avoidance Learning; D001930:Brain Injuries; D003513:Cycloheximide; D004195:Disease Models, Animal; D005663:Furans / Q000627:therapeutic use*; D008297:Male; D009257:Nafronyl / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012153:Retention, Psychology; D012601:Scopolamine
D005663:Furans; D009257:Nafronyl; D003513:Cycloheximide; D012601:Scopolamine